ATHE 6-K

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-163

UNDERTHE SECURITIES EXCHANGE ACT OF 1934

---

Forthe month of September 2024

AlterityTherapeutics Limited

(Name of Registrant)

Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

---

Form 20-F ☒       Form 40-F ☐

---

ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980and 333-228671) and ourRegistration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417and 333-250076)

ALTERITYTHERAPEUTICS LIMITED

(adevelopment stage enterprise)

The following exhibits are submitted:

99.1	Change of Director's Interest Notice x 2

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Alterity Therapeutics Limited
By:	/s/ Geoffrey P. Kempler
	Geoffrey P. Kempler
	Chairman

Date: September 20, 2024

2

Exhibit 99.1

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.. Amended 01/01/11

---

Name of Entity:	Alterity<br> Therapeutics Limited (ASX:ATH)
ABN:	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Brian Meltzer
Date of Last Notice:	11 January 2024

Part 1 - Changeof director’s relevant interests in securities

In the case of a trust, this includesinterests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and<br>indirect
Nature of indirect interest<br><br> <br>(including registered holder)<br><br> <br>Note: Provide details of the circumstances<br> giving rise to the relevant interest.	Related entity
Date of change	31 August 2024
No. of securities held prior to change		Shares	Options
---	---	---	---
	Direct	7,142,857	16,523,809
	Indirect	326,666	-
****	Total	7,469,523	16,523,809
Class	Unlisted<br>Options
---	---
Number acquired	****	Shares	Options
---	---	---	---
	Direct	-	-
	Indirect	-	-
****	Total	-	-
Number disposed	****	Shares	Options
	Direct	-	7,142,857
	Indirect	-	-
****	Total	-	7,142,857
+ See chapter 19 for defined terms.
---	---
11/3/2002	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br>and estimated valuation	n/a
No. of securities held after change	****	Shares	Options
---	---	---	---
	Direct	7,142,857	9,380,952
	Indirect	326,666	-
****	Total	7,469,523	9,380,952
Nature of change<br><br> <br>Example: on-market trade, off-market trade, exercise<br> of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of options without exercise or conversion
---	---

---

Part 2 –Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder<br><br> <br>(if issued securities)
Date of change
No. and class of securities to which interest related prior to change<br><br> <br>Note: Details are<br> only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br> and an estimated valuation
Interest after change

Part 3 - +ClosedPeriod

---

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A
+ See chapter 19 for defined terms.
---	---
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

---

Name of Entity:	Alterity<br> Therapeutics Limited (ASX:ATH)
ABN:	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Peter Marks
Date of Last Notice:	11 January 2024

Part 1 - Changeof director’s relevant interests in securities

In the case of a trust, this includesinterests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and<br>indirect
Nature of indirect interest<br><br> <br>(including registered holder)<br><br> <br>Note: Provide details of the circumstances<br> giving rise to the relevant interest.	Related entity
Date of change	31 August 2024
No. of securities held prior to change	****	Shares	Options
---	---	---	---
	Direct	-	7,000,000
	Indirect	7,185,986	9,523,809
****	Total	7,185,968	16,523,809
Class	Unlisted<br>Options
---	---
Number acquired	****	Shares	Options
---	---	---	---
	Direct	-	-
	Indirect	-	-
****	Total	-	-
Number disposed	****	Shares	Options
	Direct	-	-
	Indirect	-	7,142,857
****	Total	-	7,142,857
Value/Consideration<br><br><br><br>Note: If consideration is non-cash, provide details<br>and estimated valuation	****
+ See chapter 19 for defined terms.
---	---
11/3/2002	Appendix 3Y Page 3

Appendix 3Y

Change of Director’s Interest Notice

Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br>and estimated valuation	n/a
No. of securities held after change	****	Shares	Options
---	---	---	---
	Direct	-	7,000,000
	Indirect	7,185,986	2,380,952
****	Total	7,185,968	9,380,952
Nature of change<br><br> <br>Example: on-market trade, off-market trade, exercise<br> of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of unlisted options without exercise or conversion
---	---

---

Part 2 –Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder<br><br> <br>(if issued securities)
Date of change
No. and class of securities to which interest related prior to change<br><br> <br>Note: Details are<br> only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br> and an estimated valuation
Interest after change

Part 3 - +ClosedPeriod

---

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A
+ See chapter 19 for defined terms.
---	---
Appendix 3Y Page 4	01/01/2011